The plan Oxitec cooked up involves releasing genetically modified Aedes aegypti male mosquitos that would pass off a gene that's fatal to any offspring produced with wild female insects, thus trimming the population of infected mosquitos. Specifically, the FDA has stated that Oxitec's plan wouldn't cause any harm to the local environment, but the biotech firm still needs to work with a number of local, state and federal agencies before the field trial begins.

Oxitec also has to come to an agreement with the Florida Keys Mosquito Control District before enacting its field trial, something the FDA's approval will likely help with. Fusion notes that some have concerns about what removing a large portion of the Aedes aegypti mosquito population from the environment would have. The Florida Keys Mosquito Control District will speak with residents and then vote on the proposal -- if it passes it sounds like the field trial won't happen until late this year.